Therapy of infections caused by dematiaceous fungi

References

• Pang KR, Wu JJ, Huang DB, Tyring SK. Subcutaneous fungal infections. Dermatol. Ther. 17, 523–531 (2004).
   PubMedGoogle Scholar
• Ahmed AOA, van Leeuwen W, Fahal A, van de Sande W, Verbrugh H, van Belkum A. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect. Dis. 4, 566–574 (2004).
   PubMed Web of Science ®Google Scholar
• Rinaldi MG. Phaeohyphomycosis. Dermatol. Clin. 14, 147–153 (1996).
   PubMedGoogle Scholar
• Pappagianis D, Ajello L. Dematiaceous – a mycologic misnomer? J. Med. Vet. Mycol. 32, 319–321 (1994).
   PubMedGoogle Scholar
• Matsumoto T, Ajello L, Matsuda T, Szaniszlo PJ, Walsh TJ. Developments in hyalohyphomycosis and phaeohyphomycosis. J. Med. Vet. Mycol. 32(Suppl. 1), 329–349 (1994).
   PubMedGoogle Scholar
• Padhye AA, Bennett JE, McGinnis MR, Sigler L, Fliss A, Salkin IF. Biosafety considerations in handling medically important fungi. Med. Mycol. 36(Suppl. 1), 258–265 (1998).
   PubMed Web of Science ®Google Scholar
• Feng B, Wang X, Hauser M et al. Molecular cloning and characterization of WdPKS1, a gene involved in dihydroxynaphthalene melanin biosynthesis and virulence in Wangiella (Exophiala) dermatitidis. Infect. Immun. 69, 1781–1794 (2001).
   PubMed Web of Science ®Google Scholar
• Casadevall A, Rosas AL, Nosanchuk JD. Melanin and virulence in Cryptococcus neoformans. Curr. Opin. Microbiol. 3, 354–358 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobson ES. Pathogenic roles for fungal melanins. Clin. Microbiol. Rev. 13, 708–717 (2000).
   PubMed Web of Science ®Google Scholar
• Hamilton AJ, Gomez BL. Melanins in fungal pathogens. J. Med. Microbiol. 51, 189–191 (2002).
   PubMed Web of Science ®Google Scholar
• Butler MJ, Day AW. Fungal melanins: a review. Can. J. Microbiol. 44, 1115–1136 (1998).
   Web of Science ®Google Scholar
• van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob. Agents Chemother. 46, 3394–3400 (2002).
   PubMed Web of Science ®Google Scholar
• Ikeda R, Sugita T, Jacobson ES, Shinoda T. Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiol. Immunol. 47, 271–277 (2003).
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J. Clin. Microbiol. 36, 2353–2355 (1998).
   PubMed Web of Science ®Google Scholar
• National Committe for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal SusceptibilityTesting of Conidium-forming Filamentous Fungi. National Committe for Clinical Laboratory Standards, PA, USA. Approved M38-A (2002).
   Google Scholar
• National Committe for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. National Committe for Clinical Laboratory Standards, PA, USA. Approved standard M27-A (1997).
   Google Scholar
• National Committe for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. National Committe for Clinical Laboratory Standards, PA, USA. Approved standard M27-A2, Second Edition (2002).
   Google Scholar
• Caligiorne RB, Resende MA, Melillo PH, Peluso CP, Carmo FH, Azevedo V. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med. Mycol. 37, 405–409 (1999).
   PubMed Web of Science ®Google Scholar
• Guarro J, Soler L, Rinaldi MG. Pathogenicity and antifungal susceptibility of Chaetomium species. Eur. J. Clin. Microbiol. Infect. Dis. 14, 613–618 (1995).
   PubMedGoogle Scholar
• Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. 46, 62–68 (2002).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150, 101–115 (2001).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20, 121–136 (2003).
   PubMedGoogle Scholar
• McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med. Mycol. 36, 243–246 (1998).
   PubMed Web of Science ®Google Scholar
• van de Sande WW, Luijendijk A, Ahmed AO, Bakker-Woudenberg IA, van Belkum A. Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method. Antimicrob. Agents Chemother. 49, 1364–1368 (2005).
   PubMedGoogle Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36, 2950–2956 (1998).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46, 1032–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Al Abdely HM, Najvar L, Bocanegra R et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (‘Ramichloridium mackenziei’). Antimicrob. Agents Chemother. 44, 1159–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38, 155–159 (2000).
   PubMed Web of Science ®Google Scholar
• Ehrenfreund-Kleinman T, Domb AJ, Jaffe CL, Nasereddin A, Leshem B, Golenser J. The effect of amphotericin B derivatives on Leishmania and immune functions. J. Parasitol. 91, 158–163 (2005).
   PubMedGoogle Scholar
• Simitsopoulou M, Roilides E, Dotis J et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob. Agents Chemother. 49, 1397–1403 (2005).
   PubMed Web of Science ®Google Scholar
• Sutton DA, Slifkin M, Yakulis R, Rinaldi MG. U.S. case report of cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (R. mackenziei): criteria for identification, therapy, and review of other known dematiaceous neurotropic taxa. J. Clin. Microbiol. 36, 708–715 (1998).
   PubMed Web of Science ®Google Scholar
• Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy 20, 1335–1355 (2000).
   PubMed Web of Science ®Google Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46, 171–179 (2000).
   PubMed Web of Science ®Google Scholar
• Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 33, 129–140 (1987).
   PubMed Web of Science ®Google Scholar
• Andrade TS, Castro LG, Nunes RS, Gimenes VM, Cury AE. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses 47, 216–221 (2004).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J. Clin. Microbiol. 39, 954–958 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. 42, 741–745 (1998).
   PubMed Web of Science ®Google Scholar
• Nucci M, Akiti T, Barreiros G et al. Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: newly described causes of bloodstream infection. J. Clin. Microbiol. 39, 514–518 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58, 612–624 (2004).
   PubMed Web of Science ®Google Scholar
• Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 42, 313–318 (1998).
   PubMed Web of Science ®Google Scholar
• Serena C, Ortoneda M, Capilla J et al. In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob. Agents Chemother. 47, 3161–3164 (2003).
   PubMed Web of Science ®Google Scholar
• Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45, 2151–2153 (2001).
   PubMed Web of Science ®Google Scholar
• Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br. J. Dermatol. 141, 36–40 (1999).
   PubMed Web of Science ®Google Scholar
• Hosseini-Yeganeh M, McLachlan AJ. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob. Agents Chemother. 46, 2219–2228 (2002).
   PubMed Web of Science ®Google Scholar
• Ryder NS, Frank I. Interaction of terbinafine with human serum and serum proteins. J. Med. Vet. Mycol. 30, 451–460 (1992).
   PubMedGoogle Scholar
• Deresinski SC, Stevens DA. Caspofungin. Clin. Infect. Dis. 36, 1445–1457 (2003).
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JFGM, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 44, 470–472 (2000).
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47, 106–117 (2003).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J. Clin. Microbiol. 41, 3981–3985 (2003).
   PubMed Web of Science ®Google Scholar
• Corrado ML, Kramer M, Cummings M, Eng RH. Susceptibility of dematiaceous fungi to amphotericin B, miconazole, ketoconazole, flucytosine and rifampin alone and in combination. Sabouraudia 20, 109–113 (1982).
   PubMedGoogle Scholar
• Polak A. Antimycotic therapy of experimental infections caused by dematiaceous fungi. Sabouraudia 22, 279–289 (1984).
   PubMedGoogle Scholar
• Graybill JR, Najvar LK, Johnson E, Bocanegra R, Loebenberg D. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob. Agents Chemother. 48, 2288–2291 (2004).
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Gil-Lamaignere C, Avramidis N et al. Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48, 3801–3805 (2004).
   PubMed Web of Science ®Google Scholar
• Ortoneda M, Capilla J, Pujol I et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J. Antimicrob. Chemother. 49, 525–529 (2002).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ryder JE, Baran R, Summerbell RC. Non-dermatophyte onychomycosis. Dermatol. Clin. 21, 257–268 (2003).
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Lorenzi S, Iorizzo M. Treatment of nondermatophyte mold and Candida onychomycosis. Dermatol. Clin. 21, 491–497 (2003).
   PubMed Web of Science ®Google Scholar
• Sutton DA, Rinaldi MG, Kielhofner M. First US report of subcutaneous phaeohyphomycosis caused by Veronaea botryosa in a heart transplant recipient and review of the literature. J. Clin. Microbiol. 42, 2843–2846 (2004).
   PubMed Web of Science ®Google Scholar
• Kimura M, Goto A, Furuta T, Satou T, Hashimoto S, Nishimura K. Multifocal subcutaneous phaeohyphomycosis caused by Phialophora verrucosa. Arch. Pathol. Lab. Med. 127, 91–93 (2003).
   PubMed Web of Science ®Google Scholar
• Murayama N, Takimoto R, Kawai M, Hiruma M, Takamori K, Nishimura K. A case of subcutaneous phaeohyphomycotic cyst due to Exophiala jeanselmei complicated with systemic lupus erythematosus. Mycoses 46, 145–148 (2003).
   PubMed Web of Science ®Google Scholar
• Agarwal A, Singh SM. A case of cutaneous phaeohyphomycosis caused by Exserohilum rostratum, its in vitro sensitivity and review of literature. Mycopathologia 131, 9–12 (1995).
   PubMedGoogle Scholar
• Allred BJ. Subcutaneous phaeohyphomycosis due to Exophiala jeanselmei in an immunosuppressed patient: case report. NZ Med. J. 103, 321–322 (1990).
   PubMedGoogle Scholar
• Chuan MT, Wu MC. Subcutaneous phaeohyphomycosis caused by Exophiala jeanselmei: successful treatment with itraconazole. Int. J. Dermatol. 34, 563–566 (1995).
   PubMedGoogle Scholar
• Campos-Takaki GM, Jardim ML. Report of chronic subcutaneous abscesses caused by Exophiala spinifera. Mycopathologia 127, 73–76 (1994).
   PubMed Web of Science ®Google Scholar
• Koga T, Matsuda T, Matsumoto T, Furue M. Therapeutic approaches to subcutaneous mycoses. Am. J. Clin. Dermatol. 4, 537–543 (2003).
   PubMedGoogle Scholar
• Summerbell RC, Krajden S, Levine R, Fuksa M. Subcutaneous phaeohyphomycosis caused by Lasiodiplodia theobromae and successfully treated surgically. Med. Mycol. 42, 543–547 (2004).
   PubMed Web of Science ®Google Scholar
• Studahl M, Backteman T, Stalhammar F, Chryssanthou E, Petrini B. Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery. Acta Paediatr. 92, 980–982 (2003).
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Carrasco-Gerard E, Saul A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 44, 1–7 (2001).
   PubMed Web of Science ®Google Scholar
• Castro LG, Pimentel ER, Lacaz CS. Treatment of chromomycosis by cryosurgery with liquid nitrogen: 15 years' experience. Int. J. Dermatol. 42, 408–412 (2003).
   PubMed Web of Science ®Google Scholar
• Minotto R, Bernardi CDV, Mallmann LF, Edelweiss MIA, Scrofernekr ML. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J. Am. Acad. Dermatol. 44, 585–592 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med. Mycol. 40, 529–534 (2002).
   PubMed Web of Science ®Google Scholar
• Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea 21, 555–559 (2002).
   PubMed Web of Science ®Google Scholar
• Srinivasan M. Fungal keratitis. Curr. Opin. Ophthalmol. 15, 321–327 (2004).
   PubMedGoogle Scholar
• Garg P, Gopinathan U, Choudhary K, Rao GN. Keratomycosis: clinical and microbiologic experience with dematiaceous fungi. Ophthalmology 107, 574–580 (2000).
   PubMed Web of Science ®Google Scholar
• Bharathi MJ, Ramakrishnan R, Vasu S, Meenakshi R, Palaniappan R. Epidemiological characteristics and laboratory diagnosis of fungal keratitis. A three-year study. Indian J. Ophthalmol. 51, 315–321 (2003).
   PubMedGoogle Scholar
• Chowdhary A, Singh K. Spectrum of fungal keratitis in North India. Cornea 24, 8–15 (2005).
   PubMed Web of Science ®Google Scholar
• Wilhelmus KR, Jones DB. Curvularia keratitis. Trans. Am. Ophthalmol. Soc. 99, 111–130 (2001).
   PubMedGoogle Scholar
• Thomas PA. Fungal infections of the cornea. Eye 17, 852–862 (2003).
   PubMed Web of Science ®Google Scholar
• Hernandez PC, Llinares TF, Burgos SJ, Selva OJ, Ordovas Baines JP. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann. Pharmacother. 38, 414–417 (2004).
   PubMedGoogle Scholar
• Ferguson BJ. Definitions of fungal rhinosinusitis. Otolaryngol. Clin. North Am. 33, 227–235 (2000).
   PubMed Web of Science ®Google Scholar
• Schubert MS. Allergic fungal sinusitis: pathogenesis and management strategies. Drugs 64, 363–374 (2004).
   PubMed Web of Science ®Google Scholar
• Houser SM, Corey JP. Allergic fungal rhinosinusitis: pathophysiology, epidemiology, and diagnosis. Otolaryngol. Clin. North Am. 33, 399–409 (2000).
   PubMedGoogle Scholar
• Kuhn FA, Javer AR. Allergic fungal rhinosinusitis: perioperative management, prevention of recurrence, and role of steroids and antifungal agents. Otolaryngol. Clin. North Am. 33, 419–433 (2000).
   PubMed Web of Science ®Google Scholar
• Greenberger PA. Allergic bronchopulmonary aspergillosis. J. Allergy Clin. Immunol. 110, 685–692 (2002).
   PubMed Web of Science ®Google Scholar
• Venarske DL, deShazo RD. Sinobronchial allergic mycosis: the SAM syndrome. Chest 121, 1670–1676 (2002).
   PubMed Web of Science ®Google Scholar
• Saenz RE, Brown WD, Sanders CV. Allergic bronchopulmonary disease caused by Bipolaris hawaiiensis presenting as a necrotizing pneumonia: case report and review of literature. Am. J. Med. Sci. 321, 209–212 (2001).
   PubMedGoogle Scholar
• Lake FR, Froudist JH, McAleer R, Gillon RL, Tribe AE, Thompson PJ. Allergic bronchopulmonary fungal disease caused by Bipolaris and Curvularia. Aust. NZ J. Med. 21, 871–874 (1991).
   PubMedGoogle Scholar
• Mroueh S, Spock A. Allergic bronchopulmonary disease caused by Curvularia in a child. Pediatr. Pulmonol. 12, 123–126 (1992).
   PubMedGoogle Scholar
• Wark PAB, Gibson PG. Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment. Respirology 6, 1–7 (2001).
   PubMedGoogle Scholar
• Burns KE, Ohori NP, Iacono AT. Dactylaria gallopava infection presenting as a pulmonary nodule in a single-lung transplant recipient. J. Heart Lung Transplant. 19, 900–902 (2000).
   PubMed Web of Science ®Google Scholar
• Greig JR, Khan MA, Hopkinson NS, Marshall BG, Wilson PO, Rahman SU. Pulmonary infection with Scedosporium prolificans in an immunocompetent individual. J. Infect. 43, 15–17 (2001).
   PubMed Web of Science ®Google Scholar
• Odell JA, Alvarez S, Cvitkovich DG, Cortese DA, McComb BL. Multiple lung abscesses due to Ochroconis gallopavum, a dematiaceous fungus, in a nonimmunocompromised wood pulp worker. Chest 118, 1503–1505 (2000).
   PubMed Web of Science ®Google Scholar
• Tamm M, Malouf M, Glanville A. Pulmonary Scedosporium infection following lung transplantation. Transpl. Infect. Dis. 3, 189–194 (2001).
   PubMedGoogle Scholar
• Mazur JE, Judson MA. A case report of a Dactylaria fungal infection in a lung transplant patient. Chest 119, 651–653 (2001).
   PubMed Web of Science ®Google Scholar
• Manian FA, Brischetto MJ. Pulmonary infection due to Exophiala jeanselmei: successful treatment with ketoconazole. Clin. Infect. Dis. 16, 445–446 (1993).
   PubMedGoogle Scholar
• Carter E, Boudreaux C. Fatal cerebral phaeohyphomycosis due to Curvularia lunata in an immunocompetent patient. J. Clin. Microbiol. 42, 5419–5423 (2004).
   PubMedGoogle Scholar
• Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin. Infect. Dis. 38, 206–216 (2004).
   PubMed Web of Science ®Google Scholar
• Levin TP, Baty DE, Fekete T, Truant AL, Suh B. Cladophialophora bantiana brain abscess in a solid-organ transplant recipient: case report and review of the literature. J. Clin. Microbiol. 42, 4374–4378 (2004).
   PubMed Web of Science ®Google Scholar
• Fica A, Diaz MC, Luppi M et al. Unsuccessful treatment with voriconazole of a brain abscess due to Cladophialophora bantiana. Scand. J. Infect. Dis. 35, 892–893 (2003).
   PubMed Web of Science ®Google Scholar
• Trinh JV, Steinbach WJ, Schell WA, Kurtzberg J, Giles SS, Perfect JR. Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. Med. Mycol. 41, 339–345 (2003).
   PubMed Web of Science ®Google Scholar
• de Lastours V, Lefort A, Zappa M, Dufour V, Belmatoug N, Fantin B. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur. J. Clin. Microbiol. Infect. Dis. 22, 297–299 (2003).
   PubMed Web of Science ®Google Scholar
• Nesky MA, McDougal EC, Peacock JE Jr. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis. 31, 673–677 (2000).
   PubMed Web of Science ®Google Scholar
• Al Abdely HM, Alkhunaizi AM, Al Tawfiq JA, Hassounah M, Rinaldi MG, Sutton DA. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med. Mycol. 43, 91–95 (2005).
   PubMedGoogle Scholar
• Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin. Infect. Dis. 34, 467–476 (2002).
   PubMed Web of Science ®Google Scholar
• Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis. 22, 111–113 (2003).
   PubMed Web of Science ®Google Scholar
• Negroni R, Helou SH, Petri N, Robles AM, Arechavala A, Bianchi MH. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin. Infect. Dis. 38, E15–E20 (2004).
   Web of Science ®Google Scholar
• Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin. Infect. Dis. 37, 728–732 (2003).
   PubMed Web of Science ®Google Scholar
• Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44, 343–499 (1998).
   PubMedGoogle Scholar